NON HODGKIN LYMPHOMA (NHL)
Clinical trials for NON HODGKIN LYMPHOMA (NHL) explained in plain language.
Never miss a new study
Get alerted when new NON HODGKIN LYMPHOMA (NHL) trials appear
Sign up with your email to follow new studies for NON HODGKIN LYMPHOMA (NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new injection called OriV508 in 40 adults with multiple myeloma or non-Hodgkin lymphoma that has returned or not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking at how well it works agai…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New immune cell shot targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called LV009 injection for people with certain blood cancers (non-Hodgkin lymphoma and acute lymphoblastic leukemia) that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified …
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Double-target CAR-T therapy takes on blood cancers that won't quit
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to treat adults with B-cell blood cancers like lymphoma and leukemia that have not responded to other treatments. The therapy uses the patient's own immune cells, w…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New drug NB02 tested for tough lymphoma cases
Disease control Recruiting nowThis early-phase trial tests a new drug called NB02 (posseltinib) in about 9 adults with certain types of Non-Hodgkin lymphoma (follicular, mantle cell, or marginal zone) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose …
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1 • Sponsor: NOBO Medicine • Aim: Disease control
Last updated May 18, 2026 12:01 UTC